NASDAQ : BBOT
BridgeBio Oncology Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.7 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 216.47M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 210.06M |
| Enterprise Value | -131.56M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 80.17M |
| Shares Outstanding | 80.17M |
| Shares Change (YoY) | +12,503.20% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 45.55% |
| Float | 35.81M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.69 |
| Quick Ratio | 4.38 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -81.92% |
| Return on Assets (ROA) | -47.10% |
| Return on Invested Capital (ROIC) | -55.27% |
| Return on Capital Employed (ROCE) | -61.20% |
| Weighted Average Cost of Capital (WACC) | 7.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.07M |
| Employee Count | 88 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.65 |
| 52-Week Price Change | -77.36% |
| 50-Day Moving Average | 5.00 |
| 200-Day Moving Average | 8.14 |
| Relative Strength Index (RSI) | 23.98 |
| Average Volume (20 Days) | 586,368 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.85M |
| Short Previous Month | 3.37M |
| Short % of Shares Out | 4.80% |
| Short % of Float | 10.74% |
| Short Ratio (days to cover) | 6.51 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -198.96M |
| Pretax Income | -182.11M |
| Net Income | -182.11M |
| EBITDA | -198.65M |
| EBIT | -198.96M |
| Earnings Per Share (EPS) | -$2.56 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 225.71M |
| Total Debt | 2.51M |
| Net Cash | 341.62M |
| Net Cash Per Share | $4.26 |
| Equity (Book Value) | 323.11M |
| Book Value Per Share | 4.03 |
| Working Capital | 190.74M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -151.28M |
| Capital Expenditures | -284,000 |
| Depreciation & Amortization | 307,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -151.56M |
| FCF Per Share | -$1.89 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12,503.20% |
| Shareholder Yield | -12,503.20% |
| Earnings Yield | -97.68% |
| FCF Yield | -72.15% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $23.55 |
| Price Target Difference | 798.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |